DreaMed Diabetes aspires to change the way diabetes is treated all over the world by delivering treatment optimization products and enhancing the lives of insulin-dependent patients and their caregivers. The company was established in 2014, commercializing the first artificial pancreas technology which was published in the NEJM. Ever since, DreaMed Diabetes has been vigorously working on decision support tools in the diabetes management space and has become the first and only company in the world to receive FDA clearance for a decision support system using data from CGM/SMBG and insulin pumps.
Our founders are all physicians and engineers. The products we develop are based on real insights from clinical practice of diabetes specialists, physicians, and clinical researchers from the top diabetes centers worldwide.
We give great importance to privacy, security, quality, and regulatory matters and operate under our strict quality management system and in compliance with ISO 27001, GDPR and HIPAA. Our product is FDA cleared.